Stocktoria
HALOZYME THERAPEUTICS, INC. HALO
HALOZYME THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M | $443.3M | $267.6M | $196.0M | $151.9M | $316.6M | $146.7M |
| R&D expense | — | $79.0M | $76.4M | $66.6M | $35.7M | $34.2M | $140.8M | $150.3M | $150.6M | $150.8M |
| SG&A expense | $207.1M | $154.3M | $149.2M | $143.5M | $50.3M | $45.7M | $77.3M | $60.8M | $53.8M | $45.9M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M | -$67.6M | -$69.3M | $81.0M | -$83.2M |
| Interest expense | — | — | $18.8M | $16.9M | $7.5M | $20.4M | $11.6M | $18.0M | $22.0M | $20.0M |
| Income tax | $150.0M | $113.0M | $66.7M | $46.8M | -$154.2M | $217,000 | -$11,000 | $537,000 | -$1.4M | $1.2M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | -$72.2M | -$80.3M | $63.0M | -$103.0M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M | $55.5M | -$85.4M | -$49.5M | $134.1M | -$50.4M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M | $53.0M | -$89.5M | -$54.2M | $132.7M | -$53.5M |
| Cash & equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M | $147.7M | $120.2M | $57.9M | $168.7M | $66.8M |
| Inventory | $176.5M | $141.9M | $127.6M | $100.1M | $53.9M | $60.7M | $29.4M | $22.6M | $5.1M | $14.6M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B | $579.9M | $565.9M | $440.2M | $519.9M | $261.5M |
| Total liabilities | $2.5B | $1.7B | $1.6B | $1.7B | — | — | — | — | — | — |
| Shareholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M | $151.0M | $91.8M | $248.9M | $208.4M | -$32.5M |
Growth · year-over-year · Revenue CAGR 28.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +37.6% | +22.4% | +25.6% | +48.9% | +65.7% | +36.5% | +29.1% | -52.0% | +115.8% | +8.6% |
| Net income growth | -28.6% | +57.7% | +39.3% | -49.8% | +212.0% | — | — | -227.6% | — | — |
| EPS growth | -25.4% | +63.3% | +45.8% | -47.4% | +201.1% | — | — | -224.4% | — | — |
| Free cash flow growth | +37.6% | +25.5% | +58.6% | -21.0% | +462.8% | — | — | -140.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.